Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial | GenomeWeb

Vertex Pharmaceuticals has announced positive interim results this month from the second part of an ongoing Phase II trial examining a combined regimen of its approved drug Kalydeco and its newer treatment VX-809 in cystic fibrosis patients with the F508del mutation. After 56 days of treatment, adult subjects homozygous for the mutation have shown significant improvement in lung function, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.